Compare DYN & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DYN | ASH |
|---|---|---|
| Founded | 1984 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2020 | 2016 |
| Metric | DYN | ASH |
|---|---|---|
| Price | $18.85 | $78.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $34.33 | ★ $82.00 |
| AVG Volume (30 Days) | ★ 2.4M | 551.0K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $1,824,000,000.00 |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $4.33 |
| P/E Ratio | ★ N/A | $178.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.00 | $48.00 |
| 52 Week High | $27.31 | $79.50 |
| Indicator | DYN | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 71.24 |
| Support Level | $16.65 | $66.79 |
| Resistance Level | $19.46 | $78.25 |
| Average True Range (ATR) | 0.90 | 2.11 |
| MACD | 0.40 | 0.47 |
| Stochastic Oscillator | 93.76 | 82.82 |
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.